DR. SETH JOEL PAGE M.D. NPI 1518974948

NPI Details

DR. Seth Joel Page, M.D. is a hematology and oncology internal medicine in Wichita, KS with 22 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. DR. Seth Joel Page, M.D. NPI is 1518974948. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: UNIVERSITY OF KANSAS SCHOOL OF MED (KC/WICH/SAL)
Graduation Year:2004

The provider's business location address is:

3243 E MURDOCK ST
SUITE 300
WICHITA, KS
ZIP 67208-052
Phone: (316) 262-4467

The NPI 1518974948 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram (HCPCS:Q5101)
• Injection, ferric carboxymaltose, 1 mg (HCPCS:J1439)
• Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram (HCPCS:Q5110)
• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, epoetin alfa, (for non-esrd use), 1000 units (HCPCS:J0885)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg (HCPCS:Q5107)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1568)
• Microscopic examination for white blood cells with manual cell count (HCPCS:85007)
• Complete blood cell count (red cells, white blood cell, platelets), automated test (HCPCS:85027)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, pegfilgrastim-jmdb, biosimilar, (fulphila), 0.5 mg (HCPCS:Q5108)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Flow cytometry technique for dna or cell analysis, each additional marker (HCPCS:88185)
• Magnesium level (HCPCS:83735)
• Cyclophosphamide, 100 mg (HCPCS:J9070)
• Phosphate level (HCPCS:84100)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Ferritin (blood protein) level (HCPCS:82728)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Injection, doxorubicin hydrochloride, 10 mg (HCPCS:J9000)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Telephone medical discussion with physician, 5-10 minutes (HCPCS:99441)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Telephone medical discussion with physician, 11-20 minutes (HCPCS:99442)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Unclassified drugs (HCPCS:J3490)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries (HCPCS:A9552)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Nuclear medicine study from skull base to mid-thigh with ct scan (HCPCS:78815)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Thyroxine (thyroid chemical), free (HCPCS:84439)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Creatinine level to test for kidney function or muscle injury (HCPCS:82570)
• Total protein level, urine (HCPCS:84156)
• Blood test, basic group of blood chemicals (calcium, total) (HCPCS:80048)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Folic acid level, serum (HCPCS:82746)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Administration of influenza virus vaccine (HCPCS:G0008)
• Influenza vaccine, quadrivalent, 0.5 ml dosage (HCPCS:90688)
• Vitamin d-3 level (HCPCS:82306)
• Injection of drug or substance into vein (HCPCS:96374)
• Blood test, clotting time (HCPCS:85610)
• Ct scan of chest with contrast (HCPCS:71260)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Ct scan of abdomen and pelvis with contrast (HCPCS:74177)
• Manual urinalysis test with examination using microscope, non-automated (HCPCS:81000)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• Red blood count automated, with additional calculations (HCPCS:85046)
• Uric acid level, blood (HCPCS:84550)
• Flow cytometry technique for dna or cell analysis, first marker (HCPCS:88184)
• Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml (HCPCS:Q9965)
• Red blood cell sedimentation rate, to detect inflammation, non-automated (HCPCS:85651)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Red blood count, automated test (HCPCS:85045)

The enumeration date for this NPI number is 8/1/2006 and was last updated on 8/8/2012.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: